Request appointment
1275 York AvenueNew York, NY 10065
Overview of Dr. Curran
Dr. Kevin Curran is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and New York-Presbyterian Hospital. He received his medical degree from Georgetown University School of Medicine and has been in practice 22 years. Dr. Curran accepts several types of health insurance, listed below. He is one of 107 doctors at Memorial Sloan Kettering Cancer Center and one of 133 doctors at New York-Presbyterian Hospital who specialize in Pediatric Hematology & Oncology. He has more than 90 publications and over 500 citings.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2007 - 2010
Tufts Medical CenterResidency, Pediatrics, 2004 - 2007
Georgetown University School of MedicineClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2007 - 2026
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
- T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy Start of enrollment: 2017 Dec 29
Roles: Contact
Publications & Presentations
PubMed
- HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.Kevin O McNerney, Soyang Kwon, Swati Naik, Vanessa A Fabrizio, Gabriela Llaurador Caraballo
Blood Advances. 2026-07-17 - IL7-Receptor-Targeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic Leukemia.Hocine R Hocine, Undrakh Ganbaatar, Alfredo Amador-Molina, Srijita Banerjee, Kyohei Misawa
Nature Communications. 2026-07-15 - 4 citationsCXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.Joseph M Rocco, Joseph H Oved, Rikita J Patel, A Zara Herskovits, Namitha Nair
Blood. 2026-02-26
Abstracts/Posters
- Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALLKevin J. Curran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...Kevin J. Curran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Turn Biotechnologies Announces Landmark Study to Assess Effectiveness of ERA™ Therapy in Restoring Bone MarrowDecember 3rd, 2024- Longevity Investment Bulletin: Mikra, Celmatix, LyGenesis and MoreApril 14th, 2023
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois Blue Advantage HMO
BCBS Illinois BlueChoice Select
BCBS Illinois HMO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Coventry Health Care PPO Platinum
Empire BCBS HMO
Empire BCBS PPOFirst Health PPO
GHI PPO
Great West PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
